{"title":"达帕格列净对糖尿病肾病患者骨和矿物质代谢生物标志物的短期影响：前瞻性观察研究","authors":"Tugba Islek , Safak Mirioglu , Meltem Gursu , Rumeyza Kazancioglu , Metin Demirel , Sahabettin Selek , Omer Celal Elcioglu","doi":"10.1016/j.nefro.2024.06.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>There is still a lack of information regarding the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on bone and mineral metabolism in patients with diabetes and chronic kidney disease (CKD). Therefore, we aimed to investigate the effects of SGLT2i in a cohort of patients suffering from diabetic kidney disease (DKD).</div></div><div><h3>Methods</h3><div>In this prospective observational study, patients with type 2 diabetes and biopsy-proven diabetic nephropathy or presumptive DKD with eGFR levels ≥20 ml/min/1.73m2 and 25-OH vitamin D levels ≥20 ng/dl were included. 41 used SGLT2i (study group) and 39 continued their current treatment regimens (control group). Serum FGF-23, sclerostin, osteoprotegerin (OPG), and hydroxyproline levels were measured at baseline, 1 month and 3 months after treatment.</div></div><div><h3>Results</h3><div>Mean age of all patients was 67<!--> <!-->±<!--> <!-->9.3 years, and 48 (60%) were female. All patients in the study group used dapagliflozin. Taking into account the renal functions at the commencement of the study, the eGFR values for the study group and the control group were 51.2<!--> <!-->±<!--> <!-->15.6 and 44.6<!--> <!-->±<!--> <!-->16.9<!--> <!-->ml/min/1.73m<sup>2</sup>, respectively (p<!--> <!-->=<!--> <!-->0.01). After three months, these values were observed to be 47.4<!--> <!-->±<!--> <!-->16.7 and 44.3<!--> <!-->±<!--> <!-->18.8 ml/min/1.73m<sup>2</sup> (p<!--> <!-->=<!--> <!-->0.43), respectively. At baseline, OPG levels were higher in the study group (p<!--> <!-->=<!--> <!-->0.025) but there were no differences between the groups in terms of FGF-23 and sclerostin levels (p<!--> <!-->=<!--> <!-->0.670 and p<!--> <!-->=<!--> <!-->0.467, respectively). Levels of OPG, FGF-23, and sclerostin significantly decreased throughout 3 months of treatment with dapagliflozin (p<!--> <!--><<!--> <!-->0.001 for all). Hydroxyproline levels also declined but did not reach to statistical significance (p<!--> <!-->=<!--> <!-->0.075). Multiple linear regression models revealed that treatment with SGLT2i was associated with the change in levels of sclerostin (β=0.303, p<!--> <!-->=<!--> <!-->0.011) and OPG (β=0.210, p<!--> <!-->=<!--> <!-->0.010), but not with FGF-23 (β=0.089, p<!--> <!-->=<!--> <!-->0.150).</div></div><div><h3>Conclusions</h3><div>FGF-23, sclerostin and OPG levels significantly declined after treatment with dapagliflozin for 3 months.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 6","pages":"Pages 868-876"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short-term effects of dapagliflozin on biomarkers of bone and mineral metabolism in patients with diabetic kidney disease: A prospective observational study\",\"authors\":\"Tugba Islek , Safak Mirioglu , Meltem Gursu , Rumeyza Kazancioglu , Metin Demirel , Sahabettin Selek , Omer Celal Elcioglu\",\"doi\":\"10.1016/j.nefro.2024.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>There is still a lack of information regarding the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on bone and mineral metabolism in patients with diabetes and chronic kidney disease (CKD). Therefore, we aimed to investigate the effects of SGLT2i in a cohort of patients suffering from diabetic kidney disease (DKD).</div></div><div><h3>Methods</h3><div>In this prospective observational study, patients with type 2 diabetes and biopsy-proven diabetic nephropathy or presumptive DKD with eGFR levels ≥20 ml/min/1.73m2 and 25-OH vitamin D levels ≥20 ng/dl were included. 41 used SGLT2i (study group) and 39 continued their current treatment regimens (control group). Serum FGF-23, sclerostin, osteoprotegerin (OPG), and hydroxyproline levels were measured at baseline, 1 month and 3 months after treatment.</div></div><div><h3>Results</h3><div>Mean age of all patients was 67<!--> <!-->±<!--> <!-->9.3 years, and 48 (60%) were female. All patients in the study group used dapagliflozin. Taking into account the renal functions at the commencement of the study, the eGFR values for the study group and the control group were 51.2<!--> <!-->±<!--> <!-->15.6 and 44.6<!--> <!-->±<!--> <!-->16.9<!--> <!-->ml/min/1.73m<sup>2</sup>, respectively (p<!--> <!-->=<!--> <!-->0.01). After three months, these values were observed to be 47.4<!--> <!-->±<!--> <!-->16.7 and 44.3<!--> <!-->±<!--> <!-->18.8 ml/min/1.73m<sup>2</sup> (p<!--> <!-->=<!--> <!-->0.43), respectively. At baseline, OPG levels were higher in the study group (p<!--> <!-->=<!--> <!-->0.025) but there were no differences between the groups in terms of FGF-23 and sclerostin levels (p<!--> <!-->=<!--> <!-->0.670 and p<!--> <!-->=<!--> <!-->0.467, respectively). Levels of OPG, FGF-23, and sclerostin significantly decreased throughout 3 months of treatment with dapagliflozin (p<!--> <!--><<!--> <!-->0.001 for all). Hydroxyproline levels also declined but did not reach to statistical significance (p<!--> <!-->=<!--> <!-->0.075). Multiple linear regression models revealed that treatment with SGLT2i was associated with the change in levels of sclerostin (β=0.303, p<!--> <!-->=<!--> <!-->0.011) and OPG (β=0.210, p<!--> <!-->=<!--> <!-->0.010), but not with FGF-23 (β=0.089, p<!--> <!-->=<!--> <!-->0.150).</div></div><div><h3>Conclusions</h3><div>FGF-23, sclerostin and OPG levels significantly declined after treatment with dapagliflozin for 3 months.</div></div>\",\"PeriodicalId\":18997,\"journal\":{\"name\":\"Nefrologia\",\"volume\":\"44 6\",\"pages\":\"Pages 868-876\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nefrologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0211699524000560\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nefrologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0211699524000560","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Short-term effects of dapagliflozin on biomarkers of bone and mineral metabolism in patients with diabetic kidney disease: A prospective observational study
Background
There is still a lack of information regarding the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on bone and mineral metabolism in patients with diabetes and chronic kidney disease (CKD). Therefore, we aimed to investigate the effects of SGLT2i in a cohort of patients suffering from diabetic kidney disease (DKD).
Methods
In this prospective observational study, patients with type 2 diabetes and biopsy-proven diabetic nephropathy or presumptive DKD with eGFR levels ≥20 ml/min/1.73m2 and 25-OH vitamin D levels ≥20 ng/dl were included. 41 used SGLT2i (study group) and 39 continued their current treatment regimens (control group). Serum FGF-23, sclerostin, osteoprotegerin (OPG), and hydroxyproline levels were measured at baseline, 1 month and 3 months after treatment.
Results
Mean age of all patients was 67 ± 9.3 years, and 48 (60%) were female. All patients in the study group used dapagliflozin. Taking into account the renal functions at the commencement of the study, the eGFR values for the study group and the control group were 51.2 ± 15.6 and 44.6 ± 16.9 ml/min/1.73m2, respectively (p = 0.01). After three months, these values were observed to be 47.4 ± 16.7 and 44.3 ± 18.8 ml/min/1.73m2 (p = 0.43), respectively. At baseline, OPG levels were higher in the study group (p = 0.025) but there were no differences between the groups in terms of FGF-23 and sclerostin levels (p = 0.670 and p = 0.467, respectively). Levels of OPG, FGF-23, and sclerostin significantly decreased throughout 3 months of treatment with dapagliflozin (p < 0.001 for all). Hydroxyproline levels also declined but did not reach to statistical significance (p = 0.075). Multiple linear regression models revealed that treatment with SGLT2i was associated with the change in levels of sclerostin (β=0.303, p = 0.011) and OPG (β=0.210, p = 0.010), but not with FGF-23 (β=0.089, p = 0.150).
Conclusions
FGF-23, sclerostin and OPG levels significantly declined after treatment with dapagliflozin for 3 months.
期刊介绍：
Nefrología is the official publication of the Spanish Society of Nephrology. The Journal publishes articles on basic or clinical research relating to nephrology, arterial hypertension, dialysis and kidney transplants. It is governed by the peer review system and all original papers are subject to internal assessment and external reviews. The journal accepts submissions of articles in English and in Spanish languages.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
